New research published February 16, 2026, in the journal Cell sheds light on the remarkable adaptability of pancreatic cancer cells, revealing how their surroundings influence whether they grow rapidly or become resistant to chemotherapy. The study, led by researchers at NYU Langone Health, suggests that the ability of these cells to toggle between growth and survival modes is a key factor in treatment failure, making pancreatic cancer notoriously difficult to combat.
Pancreatic cancer is projected to become the second leading cause of cancer death in the United States, highlighting the urgent require for novel treatment approaches. This latest investigation focuses on a cellular process called autophagy – essentially a “self-eating” mechanism where cells break down their own components for nutrients – and how it’s regulated by the physical environment within a tumor. Understanding this interplay could unlock new strategies to overcome drug resistance and improve patient outcomes.
The research team discovered that pancreatic cancer cells respond to the extracellular matrix (ECM), the network of fibers surrounding cancer cells, by adjusting their levels of autophagy. Cells that are firmly anchored to the ECM exhibit lower levels of autophagy and a higher growth rate, while those further away increase autophagy, effectively entering a survival mode that protects them from the effects of chemotherapy. “Our findings show that the sensing of the ECM by pancreatic cancer cells enables them to switch between states of active growth and autophagic survival,” explained study first author Mohamad Assi, PhD, a postdoctoral fellow in the Department of Radiation Oncology at NYU Langone.
How Cancer Cells Sense Their Surroundings
To mimic the tumor environment, researchers grew clusters of pancreatic cancer cells in three-dimensional spheres embedded in gel-like substances. They used fluorescent proteins to track autophagy levels, finding that these levels weren’t solely determined by nutrient availability, as previously thought. Instead, the type and structure of the ECM played a crucial role. Cancer cells detect specific ECM proteins, such as laminin, through a protein on their surface called integrin subunit α3 (integrinα3). This detection triggers a cascade of events that regulate autophagy.
The study revealed a distinct population of cancer cells within pancreatic tumors: one group closely connected to the ECM, actively growing, and another, more distant group, prioritizing survival through increased autophagy. This heterogeneity presents a significant challenge for treatment, as a single drug is unlikely to effectively target all cells within the tumor. Current strategies that block autophagy, like the FDA-approved drug hydroxychloroquine, have shown limited success, potentially because they don’t reach all cancer cells or because not all cells are in a high-autophagy state.
Targeting Both Autophagy and the ECM for Improved Outcomes
Researchers explored ways to overcome this resistance. By genetically suppressing integrinα3 in laboratory settings, they forced nearly all cancer cells into a high-autophagy mode, making them more vulnerable to hydroxychloroquine. This approach resulted in a 50% reduction in cancer cell survival compared to using hydroxychloroquine alone. Further experiments involved disabling the protein NF2, which normally hinders the integrinα3 signal. Removing NF2 significantly reduced autophagy by disrupting the function of lysosomes, cellular structures critical for both autophagy and other survival pathways. This led to reduced tumor growth and cancer cell death.
These findings suggest that a more effective treatment strategy might involve simultaneously targeting both the ECM-mediated regulation of autophagy and lysosomal function. The researchers caution that current autophagy-blocking strategies are often short-lived as cancer cells adapt. A combined approach could potentially provide a more durable antitumor response.
The study involved collaboration between researchers at NYU Langone Health, the Dana-Farber Cancer Institute, Harvard Medical School, and Moores Cancer Center at UC San Diego. Funding was provided by the National Cancer Institute, the Damon Runyon Cancer Research Foundation, the Lustgarten Foundation, and Stand Up to Cancer. Alec C. Kimmelman, MD, PhD, a study author from NYU Langone, has a patent related to autophagy and has served as a consultant for several pharmaceutical companies, including Rafael/Cornerstone Pharmaceuticals, Deciphera, and AbbVie.
NYU Langone Health has consistently been ranked among the top hospitals in the nation, recognized for its commitment to quality and patient outcomes. NYU Langone Health was ranked No. 1 out of 118 comprehensive academic medical centers by Vizient Inc. For four consecutive years.
This research offers a promising new avenue for developing more effective therapies for pancreatic cancer. Future studies will focus on translating these findings into clinical trials and exploring the potential of combination therapies that target both the tumor microenvironment and the cellular mechanisms of autophagy. The ongoing investigation into the complex interplay between cancer cells and their surroundings is crucial for improving the lives of patients facing this challenging disease.
Please share your thoughts and experiences in the comments below. Your engagement helps us continue to provide informative and relevant health coverage.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
